<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Market News &#38; Stocks to Watch from StraightStocks &#187; Skin Disorders</title>
	<atom:link href="http://www.straightstocks.com/tag/skin-disorders/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.straightstocks.com</link>
	<description>Leading Stock Market News, Opinions and Commentary</description>
	<lastBuildDate>Wed, 25 Nov 2009 01:50:35 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.5</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Provectus Pharmaceuticals Inc. (PVCT.OB) Adds Second Site for Phase 2 Clinical Study of PH-10 for Psoriasis</title>
		<link>http://www.straightstocks.com/market-commentary/provectus-pharmaceuticals-inc-pvct-ob-adds-second-site-for-phase-2-clinical-study-of-ph-10-for-psoriasis/</link>
		<comments>http://www.straightstocks.com/market-commentary/provectus-pharmaceuticals-inc-pvct-ob-adds-second-site-for-phase-2-clinical-study-of-ph-10-for-psoriasis/#comments</comments>
		<pubDate>Tue, 18 Aug 2009 14:04:12 +0000</pubDate>
		<dc:creator>QualityStocks</dc:creator>
				<category><![CDATA[Market Commentary]]></category>
		<category><![CDATA[Small & Micro Cap]]></category>
		<category><![CDATA[Atopic Dermatitis]]></category>
		<category><![CDATA[ceo]]></category>
		<category><![CDATA[Craig Dees]]></category>
		<category><![CDATA[dermatology biopharmaceutical]]></category>
		<category><![CDATA[Emer]]></category>
		<category><![CDATA[final site]]></category>
		<category><![CDATA[Jason Elmer]]></category>
		<category><![CDATA[lead investigator]]></category>
		<category><![CDATA[Mount Sinai School of Medicine;]]></category>
		<category><![CDATA[National Institute of Health]]></category>
		<category><![CDATA[National Psoriasis Foundation]]></category>
		<category><![CDATA[PH]]></category>
		<category><![CDATA[PH-10]]></category>
		<category><![CDATA[principal investigator]]></category>
		<category><![CDATA[Provectus Pharmaceuticals Inc.]]></category>
		<category><![CDATA[psoriasis]]></category>
		<category><![CDATA[Skin Disorders]]></category>
		<category><![CDATA[Telex (PH-10) Headset]]></category>
		<category><![CDATA[treatment of cutaneous skin disorders]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[USD]]></category>
		<category><![CDATA[www.clinicaltrials.gov]]></category>
		<category><![CDATA[www.pvct.com]]></category>

		<guid isPermaLink="false">http://Blog.QualityStocks.net/?p=17242</guid>
		<description><![CDATA[Provectus Pharmaceuticals Inc. is quickly gaining a reputation as an up-and-coming development-stage oncology and dermatology biopharmaceutical company.  Helping to enhance this reputation and its position in the marketplace, Provectus announced the addition of Mount Sinai School of Medicine as the second and final site for its expanded Phase 2 clinical trial of the company’s [...]]]></description>
		<wfw:commentRss>http://www.straightstocks.com/market-commentary/provectus-pharmaceuticals-inc-pvct-ob-adds-second-site-for-phase-2-clinical-study-of-ph-10-for-psoriasis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Solei Systems Inc. (SOLI.PK) is “One to Watch”</title>
		<link>http://www.straightstocks.com/current-market-news/solei-systems-inc-solipk-is-%e2%80%9cone-to-watch%e2%80%9d/</link>
		<comments>http://www.straightstocks.com/current-market-news/solei-systems-inc-solipk-is-%e2%80%9cone-to-watch%e2%80%9d/#comments</comments>
		<pubDate>Thu, 29 May 2008 22:29:28 +0000</pubDate>
		<dc:creator>QualityStocks</dc:creator>
				<category><![CDATA[Current Market News]]></category>
		<category><![CDATA[OTCBB Markets]]></category>
		<category><![CDATA[Small & Micro Cap]]></category>
		<category><![CDATA[Stocks to Watch]]></category>
		<category><![CDATA[Acne Treatment]]></category>
		<category><![CDATA[Bioscience]]></category>
		<category><![CDATA[Competitive Products]]></category>
		<category><![CDATA[Cosmetic Applications]]></category>
		<category><![CDATA[Lts]]></category>
		<category><![CDATA[Medical Industries]]></category>
		<category><![CDATA[Patent Pending]]></category>
		<category><![CDATA[Phototherapy Equipment]]></category>
		<category><![CDATA[Phototherapy Treatment]]></category>
		<category><![CDATA[Pink Sheets]]></category>
		<category><![CDATA[Professional Grade Equipment]]></category>
		<category><![CDATA[Residential Customers]]></category>
		<category><![CDATA[Sensor Light]]></category>
		<category><![CDATA[Skin Disorders]]></category>
		<category><![CDATA[Skin Type]]></category>
		<category><![CDATA[Solei]]></category>
		<category><![CDATA[Spivak]]></category>
		<category><![CDATA[Tanning Industry]]></category>
		<category><![CDATA[Tanning Machine]]></category>
		<category><![CDATA[Tanning Systems]]></category>

		<guid isPermaLink="false">http://Blog.QualityStocks.net/?p=10371</guid>
		<description><![CDATA[Solei Systems Incorporated is an industry leader in the field of tanning and LED products.  As of May 2, 2008 the company began trading on the Pink Sheets exchange, and CEO Paul Spivak anticipates that, within the next few months, the company will transition onto a senior exchange.  The company consists of three [...]]]></description>
		<wfw:commentRss>http://www.straightstocks.com/current-market-news/solei-systems-inc-solipk-is-%e2%80%9cone-to-watch%e2%80%9d/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
	</channel>
</rss>
